Based on HUTCHMED's own website:
https://www.hutch-med.com/esmo2020-phase1-1b-trial-of-fruquintinib-in-patients-with-advanced-solid-tumors/
Right at the bottom (under "Disclosure") Imugene has even provided an advisory/consultancy role in 2020 for their colorectal trial.
So they definitely know of us.
Ann: Annual Report to shareholders, page-47
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
-0.002(2.82%) |
Mkt cap ! $505.0M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.1¢ | 6.9¢ | $747.5K | 10.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1363554 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 1130620 | 10 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.002 ( 1.15 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 6.9¢ | 3175836 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| IMU (ASX) Chart |